Revenue: As of FY2026 Q1, the actual value is USD 1.352 M.EPS: As of FY2026 Q1, the actual value is USD -0.81.EBIT: As of FY2026 Q1, the actual value is USD -3.612 M.<h3>First Quarter 2026 Financial Results</h3><h4>Segment Revenue</h4><ul><li>CyPath®Lung Testing Revenue: Increased approximately 114% to $361,000 in Q1 2026, compared to $169,000 in Q1 2025. Total Consolidated Revenue decreased approximately 27% to $1.4 million in Q1 2026, from $1.9 million for Q1 2025. This decline was primarily due to the discontinuation of certain unprofitable pathology services in March 2025 to focus on higher margin services, including CyPath®Lung testing. Net Revenue for Q1 2026 was $1,351,527, down from $1,853,597 in Q1 2025 .</li></ul><h4>Operational Metrics</h4><ul><li>Operating Expenses: Total operating expenses for Q1 2026 were $4,968,503, compared with $4,480,736 in Q1 2025 .<ul><li>Direct Costs and Expenses: $928,636 in Q1 2026, a 32% decrease from $1,367,860 in Q1 2025 .</li><li>Research and Development Expenses: $349,707 in Q1 2026, a 5% decrease year-over-year from $367,386 in Q1 2025 .</li><li>Clinical Development Expenses: Rose to $334,040 in Q1 2026, from $138,353 in Q1 2025 .</li><li>Selling, General and Administrative Expenses: $3,241,602 in Q1 2026, up from $2,452,549 in Q1 2025 .</li><li>Depreciation and Amortization: $114,518 in Q1 2026, compared to $154,588 in Q1 2025 .</li></ul></li><li>Loss from Operations: -$3,616,976 in Q1 2026, compared to -$2,627,139 in Q1 2025 .</li><li>Net Loss: -$3,630,610 for Q1 2026, compared with -$2,660,417 for Q1 2025 .</li></ul><h4>Cash and Cash Equivalents</h4><ul><li>Cash and Cash Equivalents: As of March 31, 2026, cash and cash equivalents were $3,098,366, compared with $6,449,782 as of December 31, 2025 .</li></ul><h4>Unique Metrics</h4><ul><li>CyPath®Lung Unit Sales: Increased 146% year-over-year in Q1 2026 .</li><li>Number of Physician Offices and Clinics Ordering CyPath®Lung: Increased 69% from Q1 2025 to Q1 2026 .</li></ul><h4>Outlook / Guidance</h4>The company anticipates accelerated growth throughout 2026, driven by commercial initiatives and increased awareness of CyPath®Lung’s benefits. Strategic priorities for the remainder of 2026 include scaling commercial execution, expanding into new geographic markets, and enhancing CyPath®Lung utilization through physician engagement. The company also plans to advance its pipeline of lung disease diagnostics by leveraging its platform .

BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 1.352 M